HOME > YCU in the World > YCU & FDA > YCU & FDA - The 2nd International Workshop
YCU & FDA - The 2nd International Workshop
"Biomarkers for Development of Biological Products and New Therapy"
Center for Biologics Evaluation and Research (CBER) of United Sates Food and Drug Administration (FDA) and Yokohama City University have worked together to mutually promote their research and education in the field of medical and life sciences on the basis of the mutual agreement in 2006. The first workshop was held on January 29-30, 2008 with the theme of "Scientific Tools to promote Biological Medical Product Success."
The subject we are going to discuss this time is "Biomarkers" which has attracted attentions in improving prevention, diagnosis and treatment, and also in accelerating the processes to develop new drugs including biologic therapeutic products. We are inviting well-known scientists from overseas including FDA as well as from Japan and offer the participants/audiences the opportunity to discuss the feasibility and processes for the application of biomarkers in the areas of medical and life sciences. The workshop also provides a forum to move forward with new ideas and technologies into the 21st Century.
Date: March 4, 2009
Venue: Hepburn Hall, Yokohama City University (Kanazawa-ku, Yokohama)
Participation Fee: Workshop 10,000yen/person
(5,000yen for person from governmental or academic organizations)
Organizer: Yokohama City University/CBER-FDA(USA)
Cooperated by: Yokohama National University and others
Supported by: Ministry of Health, Labor and Welfare, Yokohama City
Application:
The Secretariat of International Workshop by YCU & FDA
Ms. Yano, KK Sotetsu Agency
YCS5F, 5-1, Sakae-cho, Kanagawa-ku, Yokohama 221-0052
TEL 045-450-1831 FAX 045-441-8444
FDAYCUworkshop@soag.co.jp
Inquiries:
Advanced Medical Research Division, YCU: TEL 045-787-2506
What are biomarkers?
Biomarkers are substances contained in urine, serum, tissues, etc. in human body which can be used as markers for specific diseases in prevention, diagnosis and treatment, evaluating morbidity, progression and predicting hyper-sensitivity or little response to a specific drug, etc. The quantitative variation of the substance may correlate with progression or recovery of the diseases. Identifying and measuring such biomarkers can be helpful for early diagnosis, evaluating therapeutic efficacy, improving efficiency of clinical development processes, and establishing a new approach for prevention and treatment of the diseases.
------------------------------------------------------
As a tie-up event with our Workshop, the symposium titled "Innovative Integration between Medicine and Engineering based on ICT (Information & Communication Technology)" will be held on March 5, Thursday, at Pacifico Yokohama, aiming at the establishment of a medical/insurance system with innovative ICT.ĦĦTogether with specialists from overseas, the innovation of medical ICT by global co-working will be actively discussed. Please come and join them too.
Inquiries:
GCOE Office, Medical ICT Center, Yokohama National University
TEL & FAX 045-339-4490 mict@ynu.ac.jp
